Institutional
Catalio Capital Management, LP
The Brief · Catalio Capital Management, LP · Q1 2026
AI · grounded in 13F
Catalio Capital Management, LP closed its position in BridgeBio Oncology Therapeutics BBOT for a reduction of $31.4M. The fund established new positions in BridgeBio Pharma Inc BBIO for $32.1M, Definium Therapeutics Inc DFTX for $19.6M, and Incyte Corp INCY for $17.1M. Other significant exits included Eli Lilly & Co LLY at $27.9M and Johnson & Johnson JNJ at $25M. The fund also increased its share counts in UltraGenyx Pharmaceutical In RARE by 423.4% and Terns Pharmaceuticals Inc 430 by 198.7%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DNTH | DIANTHUS THERAPEUTICS INC | $104.09 | 2.44% | 405.54% | 1.65% | $47.0M | 9.82% | — | HELD |
| 2 | BBIO | BRIDGEBIO PHARMA INC | $83.54 | -2.35% | 77.69% | 67.97% | $32.1M | 6.70% | — | HELD |
| 3 | ASNDUSD | ASCENDIS PHARMA A/S | — | — | — | — | $29.5M | 6.17% | — | HELD |
| 4 | BMY | BRISTOL-MYERS SQUIBB CO | $63.10 | -0.79% | 50.70% | 16.74% | $25.5M | 5.33% | — | HELD |
| 5 | SNDX | SYNDAX PHARMACEUTICALS INC | $19.22 | -2.09% | 90.28% | 8.58% | $24.4M | 5.09% | — | HELD |
| 6 | GILD | GILEAD SCIENCES INC | $132.73 | -1.18% | 21.77% | 121.51% | $22.8M | 4.77% | — | HELD |
| 7 | 430 | TERNS PHARMACEUTICALS INC | — | — | — | — | $21.6M | 4.50% | — | HELD |
| 8 | DFTX | DEFINIUM THERAPEUTICS INC | $42.16 | 0.48% | 396.86% | -3.00% | $19.6M | 4.10% | — | HELD |
| 9 | SLNO | SOLENO THERAPEUTICS INC | — | — | — | — | $19.3M | 4.04% | — | HELD |
| 10 | BSX | BOSTON SCIENTIFIC CORP | $46.04 | -0.04% | -56.36% | 1.88% | $18.8M | 3.92% | — | HELD |
| 11 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $25.00 | -3.77% | -8.65% | -73.02% | $17.8M | 3.72% | — | HELD |
| 12 | INCY | INCYTE CORP | $127.10 | -2.18% | 71.89% | 69.87% | $17.1M | 3.58% | — | HELD |
| 13 | CYTK | CYTOKINETICS INC | $78.39 | -1.33% | 115.51% | 139.82% | $14.2M | 2.97% | — | HELD |
| 14 | NTRA | NATERA INC | $253.82 | 0.63% | 88.60% | 114.32% | $14.2M | 2.96% | — | HELD |
| 15 | CRVS | CORVUS PHARMACEUTICALS INC | $13.04 | -2.03% | 218.05% | 476.99% | $13.0M | 2.73% | — | HELD |
| 16 | GPCR | STRUCTURE THERAPEUTICS INC | $47.35 | -1.13% | 172.26% | 101.30% | $12.3M | 2.57% | — | HELD |
| 17 | MLYS | MINERALYS THERAPEUTICS INC | $26.35 | -2.23% | 94.44% | 69.67% | $11.9M | 2.48% | — | HELD |
| 18 | EW | EDWARDS LIFESCIENCES CORP | $85.76 | 2.49% | 5.91% | -28.30% | $11.6M | 2.42% | — | HELD |
| 19 | MANE | VERADERMICS INC | $107.76 | -3.39% | 189.86% | 76.63% | $11.0M | 2.29% | — | HELD |
| 20 | ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $22.56 | 0.18% | 118.39% | -37.89% | $10.0M | 2.10% | — | HELD |
| 21 | HTFL | HEARTFLOW INC | $25.04 | -2.15% | -19.67% | -25.61% | $9.8M | 2.05% | — | HELD |
| 22 | KALV | KALVISTA PHARMACEUTICALS INC | — | — | — | — | $8.6M | 1.79% | — | HELD |
| 23 | QURE | UNIQURE NV | $40.07 | 9.30% | 189.56% | 36.74% | $8.0M | 1.68% | — | HELD |
| 24 | IRON | DISC MEDICINE INC | $73.67 | -1.31% | 24.93% | -50.09% | $7.9M | 1.64% | — | HELD |
| 25 | SEPN | SEPTERNA INC | $33.61 | -1.06% | 173.22% | 31.91% | $7.1M | 1.48% | — | HELD |
| 26 | ABVX | ABIVAX SA | $118.84 | -4.34% | 72.67% | 1123.94% | $5.3M | 1.10% | — | HELD |
| 27 | DYN | DYNE THERAPEUTICS INC | $25.10 | -3.09% | 158.01% | 53.16% | $5.1M | 1.07% | — | HELD |
| 28 | ELDN | ELEDON PHARMACEUTICALS INC | $3.31 | -2.65% | -2.07% | -60.22% | $5.1M | 1.06% | — | HELD |
| 29 | KPTI | KARYOPHARM THERAPEUTICS INC | $6.86 | -3.24% | 74.55% | -92.11% | $5.0M | 1.04% | — | HELD |
| 30 | SUPN | SUPERNUS PHARMACEUTICALS | $46.57 | -2.43% | 31.91% | 70.14% | $3.2M | 0.67% | — | HELD |
| 31 | TARA | PROTARA THERAPEUTICS INC | $3.81 | -3.30% | — | — | $3.0M | 0.63% | — | HELD |
| 32 | PHAT | PHATHOM PHARMACEUTICALS INC | $11.64 | -0.17% | — | — | $2.8M | 0.58% | — | HELD |
| 33 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $27.91 | -0.25% | — | — | $2.7M | 0.56% | — | HELD |
| 34 | TYRA | TYRA BIOSCIENCES INC | $31.11 | 0.74% | — | — | $2.6M | 0.54% | — | HELD |
| 35 | IMCR | IMMUNOCORE HLDGS PLC | $33.42 | -0.27% | — | — | $2.5M | 0.53% | — | HELD |
| 36 | GUTS | FRACTYL HEALTH INC | $0.69 | -4.56% | — | — | $2.5M | 0.53% | — | HELD |
| 37 | HYPR | HYPERFINE INC | $0.89 | -2.73% | — | — | $1.4M | 0.30% | — | HELD |
| 38 | MGX | METAGENOMI THERAPEUTICS INC | $1.21 | 0.00% | — | — | $709K | 0.15% | — | HELD |
| 39 | ATAI | ATAIBECKLEY INC | $7.18 | 0.00% | — | — | $697K | 0.15% | — | HELD |
| 40 | SNSE | SENSEI BIOTHERAPEUTICS INC | — | — | — | — | $464K | 0.10% | — | HELD |
| 41 | OM | OUTSET MED INC | $4.66 | -1.27% | — | — | $454K | 0.09% | — | HELD |
Source: SEC EDGAR · accession 0001958125-26-000003. 13F discloses long positions only — shorts, foreign equities, and options are excluded.